Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease

Related Experiment Video

Updated: Jun 22, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Catherine Fiévet1, Bart Staels

  • 1Institut Pasteur, Lille, France. Bart.Staels@pasteur-lille.fr

Current Atherosclerosis Reports
|June 9, 2009
PubMed

Insights

Type 2 diabetes poses significant cardiovascular risks, even with current treatments. Peroxisome proliferator-activated receptor (PPAR) agonists offer a promising therapeutic strategy to address this persistent cardiovascular risk in diabetes patients.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management faces challenges in preventing cardiovascular complications.
  • Current therapies for lipid and blood pressure control leave substantial residual cardiovascular risk in T2DM patients.
  • Glycemic control improves microvascular outcomes but does not significantly reduce macrovascular disease risk.

Purpose of the Study:

  • To review the effectiveness of peroxisome proliferator-activated receptor (PPAR)-based therapeutics for cardiovascular disease (CVD) in T2DM.
  • To explore future prospects of novel PPAR agonists in managing cardiovascular risk in T2DM.

Main Methods:

  • Literature review focusing on PPAR-based therapeutics and cardiovascular outcomes in T2DM.
  • Analysis of the role of PPARs in lipid metabolism, glucose regulation, and inflammation relevant to T2DM complications.

Main Results:

  • PPARs are key regulators of metabolic and inflammatory pathways implicated in T2DM pathophysiology.
  • PPAR-based therapies show potential in addressing the unmet need for improved cardiovascular risk management in T2DM.
  • Existing treatments leave residual cardiovascular risk, highlighting the need for alternative strategies like PPAR agonists.

Conclusions:

  • PPARs represent a critical target for novel therapeutic strategies in T2DM.
  • PPAR agonists hold promise for mitigating the significant cardiovascular burden associated with type 2 diabetes.
  • Further research into next-generation PPAR agonists is warranted to improve cardiovascular outcomes in T2DM patients.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...